Assessment of the Mechanism of Action of Venetoclax (ABT-199) in combination with Ibrutinib (PCI-32765) in relapsed/refractory Chronic Lymphocytic Leukaemia (CLARITY)

  • Brock, Kristian (Co-Investigator)
  • Siddique, Shamyla (Principal Investigator)

Project Details

Short titleAssessment of the Mechanism of Action of Venetoclax (ABT-199) in combination with Ibrutinib (PCI-32765) in relapsed/refractory Chronic Lymphocytic Leukaemia (CLARITY)
StatusActive
Effective start/end date1/01/1631/05/24

Funding

  • BLOODWISE
  • Janssen-Cilag Limited
  • Abbvie Ltd

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.